Mental health is one of the fastest-growing healthcare challenges, demanding entirely new approaches. Which is why we are pioneering a new model – multi-disciplinary clinical services that collect critical patient data, supporting an innovation pipeline of new care models and novel drug development.
Our clinics are designed as world-class learning environments where we rigorously test new therapies, including MDMA-assisted treatment for PTSD, while advancing the development of novel compounds that target key neurotransmitters like serotonin and dopamine.
At Emyria, we are dedicated to developing groundbreaking therapies that address unmet patient needs and elevate the standard of mental health care.
Our goal? Support a future of healthier minds, with the infrastructure and insights to drive innovations that can transform mental health treatment across a wide range of conditions.
What sets our Company and its collaborators apart, is a deep commitment to making tangible inroads to address the mental health crisis – through focused research, measured investment and commercially-scalable healthcare solutions.
We are on track to become world-leaders in a promising new mental healthcare market, through our efforts to test MDMA and psilocybin for the treatment of conditions like post traumatic stress disorder (PTSD) and depression.
We are also developing novel MDMA-like compounds and exploring their potential in select neurological conditions like Parkinson’s disease, and more.
The societal and economic motivation to address mental health is real. Over 2 in 5 Australians experience a mental disorder at some time in their life. 1 in 5 Australians had a mental disorder in the past 12 months. Demand is unprecedented but, in Australia right now, 1 in 3 psychologists have closed books. We need entirely new solutions.
Emyria has the essential ingredients – purpose-built clinics, tailored technology infrastructure and the right team – to provide psychedelic treatments within the regulatory framework. We have a clear plan to scale our clinics with strong commercial foundations too, which will create immediate patient impact and real value for our investors.
Eager to learn more?
All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. These effects are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision.